首页 › 基金 › Burkehill Global Management, LP › DYN
Burkehill Global Management, LP 对 DYN 的持仓历史
DYNE THERAPEUTICS INC · 医疗保健
Burkehill Global Management, LP 在 Q3 2026 的 13F 申报中披露持有 DYN(DYNE THERAPEUTICS INC)400,000 股,市值约 US$6.4M,约占其申报组合的 0.28%,在其申报持仓中市值排名第 45 位。 Burkehill Global Management, LP 最近 5 个申报季度中有 4 个季度披露了 DYN 持仓,最早可追溯至 Q3 2025。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
Burkehill Global Management, LP 对 DYN 的持仓演变
Burkehill Global Management, LP 于 Q3 2025 首次披露 DYN 持仓:120,000 股(约 US$1.5M)。 该持仓在 Q3 2026 达到峰值 400,000 股,市值约 US$6.4M。 在 4 次申报中,Burkehill Global Management, LP 1 次增持、0 次减持、1 次保持不变。 最近一期申报(Q3 2026)显示持股 400,000 股、市值约 US$6.4M。 持仓曾出现大幅变动:Q4 2025 增持约 29% (随后一个季度股价下跌 7%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2025 | 120.00K | $1.52M | 新进 |
| Q4 2025 | 155.00K | $3.03M | 增持 |
| Q1 2026 | 155.00K | $2.81M | 持有 |
| Q3 2026 | 400.00K | $6.44M | 新进 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 DYN 与 13F 数据
DYN(DYNE THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 34 只申报持有 DYN,申报仓位最大的包括:Vestal Point Capital, LP (US$99.9M), TCG Crossover Management, LLC (US$74.3M), Frazier Life Sciences Management, L.P. (US$62.1M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 DYN 的基金
- Vestal Point Capital, LP 6.20M 股 · $99.88M · Q3 2026
- TCG Crossover Management, LLC 4.62M 股 · $74.35M · Q3 2026
- Frazier Life Sciences Management, L.P. 3.85M 股 · $62.07M · Q3 2026
- FCPM III SERVICES B.V. 3.59M 股 · $57.78M · Q3 2026
- Atlas Venture Life Science Advisors, LLC 3.44M 股 · $55.43M · Q3 2026
- MPM BioImpact LLC 3.21M 股 · $51.68M · Q3 2026
- Logos Global Management LP 3.00M 股 · $48.33M · Q3 2026
- ARMISTICE CAPITAL, LLC 2.68M 股 · $43.14M · Q3 2026
- Sofinnova Investments, Inc. 2.51M 股 · $40.45M · Q3 2026
- Siren, L.L.C. 2.43M 股 · $39.13M · Q3 2026
- Venrock Adviser, LLC 2.17M 股 · $35.02M · Q3 2026
- Bain Capital Life Sciences Investors, LLC 1.90M 股 · $30.61M · Q3 2026
更多关于 Burkehill Global Management, LP
常见问题
How long has Burkehill Global Management, LP held DYN?
Burkehill Global Management, LP has disclosed DYN holdings in 4 of the last 5 reported quarters, going back to Q3 2025.
What is Burkehill Global Management, LP's current position in DYN?
As of Q3 2026, Burkehill Global Management, LP holds 400.00K shares of DYN (DYNE THERAPEUTICS INC), valued at $6.44M, representing 0.28% of its reported portfolio and ranking #45.
Has Burkehill Global Management, LP been buying or selling DYN?
In the latest 13F filing (Q3 2026), Burkehill Global Management, LP newly opened its position in DYN. The position peaked in Q3 2026 at 400.00K shares.
Which other funds hold DYN?
Other major institutional holders of DYN include Vestal Point Capital, LP, TCG Crossover Management, LLC, Frazier Life Sciences Management, L.P., among 34 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.